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Abstract
Background: Annexin A2 (ANXA2) is a pleiotropic, calcium-dependent, phospholipid-binding protein with a
broad tissue distribution. It can be intracellular, membrane-bound, or secreted, and it exists as a monomer or
heterotetramer. The secreted ANXA2 heterotetramer signals human and murine macrophages to produce IL-1,
IL-6, and TNF-α through TLR4/MyD88- and TRIF-dependent pathways.
Methods: GL261 glioma cells were cultured in 5 % or 20 % O2. Monomeric ANXA2 (ANXA2m) was identified as a
TLR2-binding protein enriched in 5 % O2 by mass spectrometry. Purified ANXA2m and ANXA2-derived peptides
were added to TLR2-expressing reporter cells and immature dendritic cells (DCs) cells in vitro. ANXA2m was then
mixed with chicken ovalbumin (OVA) for vaccination of TLR2+/+ and TLR2−/− mice for subsequent quantification of
antigen-specific CD8+ T cell responses. The TLR2-binding region of ANXA2m was determined using various
peptides derived from the ANXA2 amino terminus on TLR2 reporter cells and in vaccinated mice.
Results: ANXA2m is overexpressed by murine glioblastoma GL261 cells grown under 5 % O2, but not atmospheric
20 % O2, and acts as an adjuvant by inducing murine and human DC maturation through TLR2. ANXA2m upregulates
CD80 and CD86 expression, enhances antigen cross-presentation, and induces the secretion of IL-12p70, TNF-α, and
IFN-γ. The amino-terminal 15 amino acids of ANXA2m are necessary and sufficient for TLR2 binding and DC activation.
Conclusion: This novel finding adds to the known functions of ANXA2 and suggests ways to exploit it as a vaccine
adjuvant. ANXA2-antigen fusion peptides could be developed for patients as “off-the-shelf” agents containing common
tumor antigens. Alternatively, they could be “personalized” and synthesized after tumor sequencing to identify
immunogenic tumor-specific neo-antigens. As the amino terminal 15 amino acids of ANXA2 are required to stimulate
TLR2 activity, a fusion peptide could be as short as 30 amino acids if one or two CD8 T cell epitopes are fused to
the ANXA2 amino terminal portion. Future work will address the efficacy of ANXA2 peptide fusions alone and in
combination with established TLR agonists to induce synergy in preclinical models of glioma as observed in
other vaccines.
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Background
Annexin A2 (ANXA2)4 is a broadly expressed member
of the annexin family of calcium-dependent, anionic
phospholipid-binding proteins. Annexins have homolo-
gous core and carboxyl domains but variable amino (N)-
terminal regions with diverse binding and functional
properties. These variable N-terminal 30 amino acid
regions, called head regions, distinguish the family
members [1]. ANXA2 was first reported as an intra-
cellular membrane-associated substrate of the pp60v-
src oncoprotein in transformed chicken embryonic fi-
broblasts [2]. ANXA2 is now known to be expressed
by many cell types in the nucleus, cytoplasm, membrane,
or extracellularly. Its many functions include membrane
organization and dynamics during endocytosis and
exocytosis, gene regulation, ion channel formation, fi-
brinolysis, and cellular transformation [3, 4]. The
subcellular localization, post-translational modifications,
and different binding partners of ANXA2 dictate its
diverse functions.
A frequent binding partner of ANXA2 is the plas-
minogen receptor protein S100A10 [5]. Upon binding to
calcium, a conformational change occurs in ANXA2m
that exposes a hydrophobic residue in its N terminus,
allowing ANXA2m to bind a S100A10 dimer. This
dimer bridges two ANXA2m to form a heterotetramer
(ANXA2t) [4]. ANXA2t binds anionic phospholipids
with high affinity and correspondingly often localizes to
the plasma membrane. ANXA2t can also be released
from cells in exosomes (after Tyr-23 phosphorylation),
via SNARE-mediated fusion with the plasma membrane,
and through transmembrane channels (when chaper-
oned by PtdIns [4, 5] P2) [6–8]. Extracellular ANXA2t
functions immunologically by inducing macrophages to
release IL-1, IL-6, and TNF-α through TLR4/MyD88-
and TRIF-dependent pathways [9].
Here we report for the first time that extracellular
ANXA2m also functions immunologically, and that the
monomeric and tetrameric forms of ANXA2 signal
through different pathways. We find that ANXA2m,
when released by cells, binds TLR2 and induces the dif-
ferentiation of murine and human antigen presenting
cells (APCs). ANXA2m induces the expression of CD80
and CD86, the secretion of IL-12, INF-γ, and TNF-α,
and enhances the cross-priming of murine and human
antigen-specific CD8+ T cells. All of these activities map
to the unique N-terminus of ANXA2m. These data,
combined with our observation that ANXA2m is over-
expressed by murine GL261 glioblastoma cells grown
under low (5 %) but not atmospheric (20 %) O2
levels, suggest ANXA2m is a novel danger-associated
molecular pattern (DAMP) that contributes to the in-
creased efficacy of tumor vaccines derived from GL261
cells grown under 5 % O2 [10].
Results and discussion
ANXA2m is an O2-regulated protein that binds TLR2
We reported that decreasing O2 from the typical tissue
culture level of 20 to 5 % enhanced the adjuvant activity
of lysates from murine GL261 glioma cells in a glioblast-
oma vaccination model [10]. This led us to hypothesize
that 5 % O2 enriched for the expression of DAMPs by
GL261 cells that, in turn, activated APCs by binding to
pattern recognition receptors. Because the pattern rec-
ognition receptor TLR2 was implicated in inflammation
following hypoxia in the brain [11], we further hypothe-
sized that TLR2 was required for recognizing O2-regu-
lated putative DAMP expression in GL261 cells.
To test these hypotheses, we pulsed splenocytes from
wildtype B6 or TLR2−/− mice with the human melano-
cyte antigen-derived gp10025–33 peptide, with or without
lysates from GL261 cells grown under 5 % or 20 % O2.
The splenocytes were then compared for their abilities
to activate purified CD8+ T cells bearing the transgenic
pmel-1 Vα1/Vβ13 TCR specific for human gp10025–33
presented by the MHC class I molecule H-2Db [12]. We
found antigen-specific CD8+ T cell activation, as measured
by IFN-γ expression, required both TLR2 and lysate from
GL261 cells cultured under 5 % O2; lysates from GL261
cells grown under 20 % O2 had no stimulatory effect on
either TLR2 sufficient or deficient splenocytes (Fig. 1a).
These data suggest TLR2 recognizes a DAMP expressed
by GL261 cells cultured under 5 % O2.
To identify the putative DAMP(s), we screened lysates
from GL261 cells cultured under 5 % O2 for TLR2-
binding molecules using immunoprecipitation. Subse-
quent mass spectrometry revealed ANXA2 was enriched
in the TLR2-binding fraction (data not shown). Immuno-
blot analysis confirmed that ANXA2 was overexpressed in
GL261 cells grown under 5 % O2 relative to 20 % O2
(Fig. 1b, top). Binding of ANXA2 and TLR2 was cor-
roborated by co-immunoprecipitation (Fig. 1b, bottom;
the <90 kDa bands in the anti-TLR2 immunoblot corres-
pond to lower molecular weight TLR2 isoforms) [13]. To-
gether these data reveal ANXA2 is an O2-regulated
protein that binds TLR2.
We next asked which form of ANXA2 bound TLR2,
and if binding resulted in signal transduction. ANXA2m
and ANXA2t were incubated in vitro with HEK-Blue
reporter cells expressing human TLR2. Secretion of alka-
line phosphatase by these reporter cells was induced by
human ANXA2m, and the TLR2-signaling positive
control Pam3CSK4 (a synthetic analogue of triacylated
lipopeptide), but not by bovine ANXA2t (Fig. 1c).
Heat denaturation or enzymatic degradation of human
ANXA2m abolished signaling, showing the TLR2 binding
moiety was proteinaceous and not a contaminating lipid
moiety (Fig. 1d). Human ANXA2m did not induce alka-
line phosphatase secretion by the HEK-Blue human TLR7
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Fig. 1 ANXA2 is enriched in physiologic oxygen, the monomeric form of which is a TLR2 agonist. a Splenocytes from B6 (TLR2+/+) and TLR2−/− mice
were pulsed with the human gp10025–33 peptide, with or without lysates from GL261 cells grown under 5 % or 20 % O2. Addition of purified pmel-1
CD8 T cells resulted in INF-γ secretion, which was quantified after 48 h by flow cytometry. The experiment was repeated three times with similar results
(the average INF-γ median fluorescence intensities [MFIs] for the three experiments were 1,868 and 4,057 for splenocytes stimulated with lysates from
GL261 cells grown under 5 % or 20 % O2, respectively). Lines indicate p <0.05 by unpaired t-test. b (top) Protein in GL261 lysate was separated
by SDS-PAGE and immunoblotted for murine ANXA2. (bottom) ANXA2 and TLR2 in GL261 lysates coimmunoprecipitate as shown by immunoblot.
Recombinant murine ANXA2 (38 kDa) and TLR2 (90 kDa) were used as controls. c & d Compounds (6.9 μM) were pulsed onto human TLR2-expressing
HEK-Blue cells, and secreted alkaline phosphatase was measured. “Proteinase K” and “heat” respectively indicate pre-treatment with the enzyme or
incubation of the protein at 56 ° C for 30 min prior to addition to reporter cells. Y axes represent colorimetric quantification of alkaline phosphatase
activity, measuring absorbance at 640 nm and normalized to media controls. The experiment was repeated three times with similar results. The mean
absorbances at 640 nm for these three experiments were 7.2 and 1.4 for ANXA2m and ANXA2t, respectively. e Same as c and d only human TLR4-
expressing HEK-Blue cells were used. The experiment was repeated three times with similar results. The mean absorbances at 640 nm for these three
experiments were 2.7 and 1.7 for ANXA2m and ANXA2t, respectively. f Same as (a) except that splenocytes from TLR4−/− mice were pulsed with the
human gp10025–33 peptide with or without human ANXA2m. The experiment was repeated three times with similar results (the average INF-γ MFIs for
the three experiments were 1,126 and 831 for peptide-pulsed splenocytes with or without human ANXA2m, respectively). Error bars are ± SEM, and
lines show p <0.01 by unpaired t-test
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reporter cell line, showing the specificity of ANXA2m
binding to TLR2 relative to TLR7 (data not shown).
Because ANXA2t binds and signals through TLR4 [9],
we tested whether ANXA2m could do the same. We
found that human ANXA2m was significantly superior
to an equimolar amount of bovine ANXA2t at activating
the HEK-Blue human TLR4 reporter cell line (Fig. 1e).
Although ANXA2m is of human origin, and ANXA2t is
bovine, the two ANXA2 proteins have identical head re-
gions and share 99 % homology overall. It is therefore
unlikely the enhanced signaling through human TLR4 of
the monomer relative to the tetramer is due to species
differences.
To determine if ANXA2m could enhance an antigen-
specific T cell response, purified CD8+ T cells bearing
the pmel-1 TCR were added to cultures of APCs from
TLR4−/− mice pulsed with the gp10025–33 peptide with
or without human ANXA2m. ANXA2m significantly en-
hanced antigen-specific activation of pmel-1 CD8+ T
cells, as measured by IFN-γ expression compared to the
peptide alone (Fig. 1f ). Together these data demonstrate
ANXA2m, and not ANXA2t, binds and signals through
TLR2, and the ANXA2m adjuvant effect does not re-
quire TLR4 or TLR7.
ANXA2m enhances murine and human antigen-specific
CD8+ T cell responses
Unlocking the cross-priming potential of the DC is a car-
dinal requirement of tumor cell vaccines. Patient-derived
immune suppression or poor immunogenicity of cell
lysates can limit the impact of co-delivered synthetic adju-
vants thereby diminishing DC activation and cross-
priming. Therefore, we next asked whether the addition of
ANXA2m to DC cultures could increase cross-priming.
To address this question, splenocytes from B6 or
TLR2−/− mice were incubated with or without human
ANXA2m and pulsed with both OVA and lysate from
GL261 cells cultured in atmospheric (20 %) O2. Mouse
and human ANXA2 proteins differ by one amino acid
residue in their head regions, and share 97 % sequence
homology overall. Antigen presentation was measured
by flow cytometry using the monoclonal antibody 25-
D1.16 (which recognizes the OVA-derived peptide SIIN-
FEKL bound to H-2Kb) [14]. The addition of human
ANXA2m to 20 % O2 derived lysates plus OVA signifi-
cantly increased surface levels of SIINFEKL/H-2Kb com-
plexes on splenic DCs (defined as being CD11c+, I-Ab+)
compared to the 20 % O2 lysates plus OVA (Fig. 2a). As
expected, splenic DCs from TLR2−/− mice did not show
enhanced levels of SIINFEKL/H-2Kb complexes follow-
ing stimulation with lysates from 5 % O2 or human
ANXA2m added to 20 % O2 (Fig. 2b). Moreover, human
ANXA2m induced robust maturation of B6 wildtype
BMDCs as evidenced by a significant increase in the
surface expression of the co-stimulatory molecules
CD80 and CD86, and secretion of cytokines IL-12p70
and TNF-α (Figs. 2c and d).
To determine if ligation of TLR2 by human ANXA2m
enhanced an antigen-specific immune response in vivo,
we used a CD8+ T-cell priming model that rapidly ex-
pands antigen-specific CD8+ T cell frequencies [15]. B6
and TLR−/− mice immunized with OVA plus human
ANXA2m were bled and the frequencies of CD8+ T cells
specific for the OVA-derived peptide, SIINFEKL, presented
by H-2Kb, were determined by flow cytometry. Human
ANXA2m significantly (P <0.001) increased the frequency
of antigen-specific peripheral blood CD8+ T cells in wild-
type but not TLR2−/− mice (Fig. 2e). Together these data
show human ANXA2m can signal through mouse TLR2 to
enhance an antigen-specific immune response.
To determine the effect of human ANXA2m on
antigen-specific human CD8+ T cell responses in vitro,
we pulsed human monocyte-derived DCs from cyto-
megalovirus (CMV)-positive and -negative donors with a
maturation cocktail and the pp65 CMV peptide in the
presence or absence of human ANXA2m [16, 17]. The
subsequent addition of patient-matched PBMCs led to a
ten-fold increase in IFN-γ secretion in CMV seropositive
samples when ANXA2m was present. This was an
antigen-specific response as PMBCs from CMV sero-
negative individuals did not secrete IFN-γ in response to
pp65 CMV plus ANXA2M (Fig. 2f ). These data reveal
ANXA2m enhances antigen-specific mouse and human
CD8+ T cell responses, and suggest human ANXA2m
can augment cross-priming in humans in vivo.
The N-terminal 15 amino acids of ANXA2m are necessary
and sufficient for TLR2 binding and signaling
Members of the annexin protein family have variable 30
aa N-terminal head regions with different sites for post-
translational modifications and bind different proteins
[1, 3, 4]. As such, they confer unique functions to each
annexin. The 15 N-terminal amino acids of ANXA2
bind to the S100A10 protein to form the ANXA2t [4].
Since ANXA2t is unable to activate TLR2, we hypothe-
sized that the N-terminus of ANXA2 was sufficient for
signaling through TLR2, and that the first 15 N terminal
amino acids were required for TLR2 activity. To test
these hypotheses, we incubated HEK-Blue TLR2 reporter
cells with peptides containing the first N-terminal 36
amino acid residues of mouse ANXA2 fused to SIIFNEKL
(ANXA2-OVA), mouse ANXA2 N-terminal residues 16–
36 fused to SIINFEKL (ANXA2ΔΝ15-OVA), or a control
peptide containing the first N-terminal 36 aa residues of
ANXA2, but with a scrambled order relative to the native
sequence, fused to SIINFEKL. Of these peptides, only
ANXA2-OVA containing the first N-terminal 36 amino
acids induced TLR2-mediated signaling (Fig. 3a). Similarly,
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only immunization with ANXA2-OVA elicited significantly
higher numbers of SIINFEKL/H-2Kb specific peripheral
blood CD8+ T cells in B6 mice compared to ANXA2ΔΝ15-
OVA or scrambled control (Fig. 3b).
Conclusions
These studies leave open the question of ANXA2 as po-
tential DAMP in vivo. ANXA2 expression is elevated in
many tumors [3, 18], and in many cancers high levels of
Fig. 2 ANXA2m enhances dendritic cell maturation and cross-priming in a TLR2-dependent manner. a Splenocytes from TLR2+/+ mice were
pulsed with the OVA248–274 peptide SIIFNEKL. SIINFEKL cross-presentation was detected 24 h later by flow cytometry using the 25-D1.16 antibody
(specific for the SIINFEKL/H-2Kb complex). Data represent the median fluorescence intensity of cells within a CD11c+MHCII+ gate. Bars signify p <0.002
by unpaired t-test. The experiment was repeated three times with similar results. The average MFIs for the three experiments were 1,236 and 274 for
peptide-pulsed CD11c+MHCII+ splenocytes with or without human ANXA2m, respectively. b Same experimental design as (a) except the splenocytes
were from TLR2−/− mice. In all three replicates there were no significant differences among the treatment groups. c BMDC cell cultures were pulsed
with 2.5 μg/ml human ANXA2m or medium. Cells were harvested and stained after 2 days. Graphs indicate the MFI for the CD11c+MHCIIhi gated
population. The average MFIs from three replicate experiments were 12,736 and 7,577 for CD80 and CD86, respectively. d Supernatants from
(c) were collected and assayed using a cytometric bead array. The averages from the three replicate experiments were 106 and 7,529 pg/ml
for IL12p70 and TNFα, respectively. Error bars are ± SEM, and lines indicate P <0.01 by unpaired t-test. e Naïve mice were vaccinated with four
sequential daily injections of OVA (days 1–4), with or without recombinant human ANXA2m and boosted once on day 7. Staining of peripheral
blood was performed on day 8. Graph represents the percentage of peripheral blood cells staining positive for the SIINFEKL/Kb dextramer within the
CD8α+ lymphocyte gate. The experiment was replicated twice with similar results with n = 4 per group (the average frequencies of dextramer-binding
CD8α + cells were 7.17 and 2.3 % in the wildtype and TLR2−/− mice, respectively). Bars denote p <0.05 by unpaired t-test. f Monocyte-derived dendritic
cells from CMV seropositive and seronegative HLA-A0201+ donors were pulsed with the pp65495–503 peptide, with or without human ANXA2m. After a
day cells were washed and autologous PBMCs were added for an additional 2 days. Soluble INF-γ was measured by bead array. The experiment was
repeated once with similar results. The averages of the two experiments were 4003 and 114 pg/ml IFN-γ for pulsed PBMCs from CMV seropositive and
seronegative individuals, respectively, and 399 pg/ml for unpulsed PBMCs from a CMV seropositive individual. Error bars are ± SEM, and lines show
p <0.01 by unpaired t-test
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ANXA2 portend a poor prognosis [19]. These observa-
tions are consistent with ANXA2 signaling through
TLR2, as TLR2-induced inflammation is implicated in
liver and colon tumor metastasis, for example [20]. Our
data suggest that immunogenic activity is absent or is
overridden by other potentially tumor-promoting func-
tions of ANXA2 [21–23], or by tumor-derived immune
suppressive mechanisms such as regulatory T cells or
myeloid-derived suppressor cells [24, 25]. It is also pos-
sible that ANXA2m is not present in great enough
quantities, is sequestered, or exists in its tetrameric
form that does not bind TLR2. The future may bring
novel approaches to increase the immunogenicity of
ANXA2 within tumor cells as a strategy to increase
anti-tumor immunity in vivo.
Methods
Animal models
C57BL/6 J (B6), Tlr2-B6.129-Tlr2tm1Kir/J (TLR2−/−),
and B6.B10ScN-Tlr4lps-del/JthJ (TLR4−/−) mice were
purchased from Jackson Laboratories and maintained
in specific pathogen-free facilities at the University
of Minnesota. The murine GL261 glioma model was
established as described [10, 16]. Mice were immu-
nized with 50 μg OVA plus 50 μg of the indicated
peptides four consecutive days, and once more,
7 days following the first vaccine [15]. All animal
studies were reviewed and approved by the Institutional
Animal Care and Use Committee at the University of
Minnesota.
Cell culture
GL261 cells were cultured in DMEM/F12 (1:1) with
L-glutamine, sodium bicarbonate, penicillin/streptomycin
(100 U/mL), B27 and N2 supplements, and 0.1-mg/mL
Normocin under 5 % or 20 % O2 as described [10].
Splenocytes and T cells were cultured in RPMI 1640 con-
taining 10 % heat-inactivated FBS, penicillin/streptomycin
(100 U/ml), and 0.1 mg/ml Normocin.
Immunoblot
GL261 cells were washed, pelleted, and lysed in radioim-
munoprecipitation assay buffer containing protease and
phosphatase inhibitors (Pierce). Lysates were diluted to
the same protein concentration and were separated by
4–12 % SDS-PAGE. The separated proteins were then
transferred to nitrocellulose, blocked, and incubated
with mouse anti-ANXA2 (BD Biosciences). Blots were
then washed and incubated with anti-mouse IgG HRP
(Jackson ImmunoResearch). After additional washing,
nitrocellulose was then incubated in ECL Plus chemilu-
minescent substrate (GE), drained, and exposed to
HyBlot CL Autoradiography film (Denville Scientific).
Immunoprecipitation
Cold GL261 lysate was adjusted to a concentration of
2 mg/ml. Primary Ab was added to 0.5 ml lysate followed
by overnight incubation at 4 °C with rocking. Protein A/G
Agarose (Santa Cruz) was added and incubated at 4 °C
with rocking. Beads were then washed, resuspended in re-
ducing sample buffer, supernatants separated by 4–12 %
Fig. 3 The N terminus of ANXA2 is necessary and sufficient for TLR2 signaling and cross-priming. a Peptides derived from the N-terminus of
ANXA2 (ANXA2-OVA, the first 36 N-terminal aa from ANXA2 fused to SIINFEKL; ANXA2(ΔN15)-OVA, ANXA2 N terminal residues 16–36 fused to
SIINFEKL; scrambled ANXA2-OVA, the first 36 N-terminal residues from ANXA2 randomly ordered and fused to SIINFEKL) were pulsed onto HEK-Blue
human TLR2 cells and secreted alkaline phosphatase was measured. The average absorbances at 640 nm from three replicate experiments were 46.7,
5.6, and 2.5 for ANXA2-OVA, ANXA2(ΔN15)-OVA, and scrambled ANXA2-OVA, respectively. b Naïve wildtype mice were vaccinated with the sequential
daily injection protocol as described in Fig. 2, with OVA plus or minus ANXA2-OVA fusion peptide and derivatives. From three replicate experiments,
the average frequencies of dextramer-binding CD8α + cells were 8.6 %, 3.2 % or 2.1 % from mice respectively immunized with ANXA2-OVA,
ANXA2(ΔN15)-OVA, or scrambled ANXA2-OVA. Error bars are ± SEM, and lines represent an unpaired t-test p <0.05
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SDS-PAGE, and transferred to nitrocellulose as described
above for immunoblotting. The Abs were mouse anti-
mouse TLR2 (Clone T2.5, Santa Cruz), mouse anti-mouse
ANXA2 (Clone 5 BD Biosciences), and anti-mouse IgG
HRP (Jackson ImmunoResearch).
Bone marrow-derived DC and TLR activity
For DC maturation experiments, B6 bone marrow-
derived DCs (BMDCs) were generated using a modified
protocol [26]. Briefly, femurs and tibias were removed
and flushed with saline. Erythrocytes were lysed, and
remaining leukocytes were washed and placed in 10 cm
dishes at 2 × 106 cells/10 ml in complete RPMI 1640
and 20 ng/ml GM-CSF (Peprotech). Non-adherent cells
were removed and media were replaced every 3 days. Six
days post-bone marrow harvest, loosely adherent cells
were washed and plated in RPMI/GM-CSF.
HEK-Blue reporter cells stably express membrane-
bound human TLR2 or human TLR4 and secrete alka-
line phosphatase upon TLR stimulation (InvivoGen).
HEK-Blue cells and BMDC swere stimulated with 50 ng/ml
of the TLR2 agonist Pam3CSK4 (Imgenex), 2.5 μg/ml
human ANXA2m (69 μM; AbD Serotec and Aviva
Systems Biology), 6.5 μg/ml purified bovine ANXA2t
(69 μM, Meridian), 5 μg/ml imiquimod, 2.6 μg/ml hu
annexin A5 (69 μM, AbD Serotec), or 200 μg/ml
ANXA2-OVA (STVHEILCKLSLEGDHSTPPSAYGSVKPY
TNFDAEEQLESIINFEKLTEWT) peptides (residues 1–
36 from ANXA2 followed by 16 OVA-derived aa). Control
peptides, one containing the same content but scrambled
order of the 36 ANXA2 aa (“Scrambled ANXA2-OVA,”
GSCTESIEALHVLELVSPYTKSHNTPDSKGDYPFAEQ-
LESIINFEKLTEWT), and one lacking the first 15 N
terminal ANXA2 aa (“ANXA2ΔΝ15-OVA,” HSTPPSA
YGSVKPYTNFDAEEQLESIINFEKLTEWT) were added
to wells at levels equimolar to ANXA2-OVA. Forty-eight
h following stimulation, BMDCs were stained and ana-
lyzed by flow cytometry, and HEK-Blue cell supernatant
was assayed for secreted embryonic alkaline phosphatase
activity using QuantiBlue colorimetric enzyme assay
(InvivoGen). Enzymatic activity was recorded as an increase
in OD640 after being normalized to media-only treatment.
Cross-priming and cross-presentation
Splenocytes from B6, TLR2−/−, or TLR4−/− mice were cul-
tured at 2 × 105 cells/well in a 96-well plate in complete
RPMI 1640 media. Splenocytes were pulsed with combi-
nations of the following: 10 μg tumor lysate, 2.5 μg/ml hu-
man ANXA2m (AbD Serotec), or 50 μg/ml hu gp10025–33
peptide (KVPRNQDWL) or an OVA-derived peptide
(EVSQLEQLESIINFEKLTEEWTSSNVM). For measure-
ment of cross-presented OVA peptide, splenocytes were
harvested, stained for CD11c, MHCII, and SIINFEKL/H-
2Kb complex, and analyzed by flow cytometry as described
below. To measure IFN-γ, CD8+ T lymphocytes were
purified from pmel-1 mouse [12] splenocytes (Miltenyi
Biotec), and 2 × 105 per well were co-cultured with unfrac-
tionated syngeneic splenocytes. Forty-eight hours after co-
culture, IFN- γ was quantified in media using a flow cyto-
metric bead array (BD Biosciences).
Cross-priming was tested in vivo through sequential daily
vaccination as described [15, 27]. Briefly, B6 or TLR2−/−
mice were vaccinated four consecutive days with 100 μg
OVA protein (with or without 1.5 μg human ANXA2m;
AbD Serotec), 40 μg ANXA2-OVA peptide, or equimolar
amounts of control peptides. Mice were boosted 3 days
following the fourth vaccine, and bled the following day
for analysis.
Flow cytometry
Analyses of labeled cell suspensions were performed on a
custom Canto II (BD) and analyzed with FlowJo software
(Tree Star, Inc.). Fluorochrome-conjugated mAbs used
were CD11c—FITC (eBioscience, clone N418), CD86—
PE (eBioscience, clone GL1), SIINFEKL-H-2Kb—PE
(eBioscience, clone 25-D1.16) CD80—APC (eBioscience,
clone 16-10A1), CD8α -APC (eBioscience, clone 53–6.7)
and I-A/I-E—eFluor450 (MHC II; eBioscience, clone M5/
114.15.2). The corresponding isotype controls were also
purchased from eBioscience. A PE—dextran-conjugated
multimer of SIINFEKL/H-2Kb was purchased from Immu-
dex (Copenhagen, Denmark).
CMV antigen cross-priming by human monocyte-derived
DCs
5 × 105 HLA-A2+ immature DCs were pulsed with
10 μg/ml of pp65495–503 (NLVPMVATV), with or with-
out addition of 2.5 μg/ml human ANXA2m and ma-
tured. Purified donor-matched CD8 T cells were added
and incubated as described previously [16].
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